Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 14/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | FPR3 | P25089 | 1/20 | 0.34 |
| ▸ | TSPO | P30536 | 1/20 | 0.34 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.34 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.34 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1762767 | 0.90 | FFAR4 (0.36) | FFAR4FPR3TSPOCRHR1TMEM97 | |
| SCHEMBL1039739 | 0.88 | MAP2K7 (0.45) | PDE4BFPR3TSPOCRHR1TMEM97 | |
| SCHEMBL29482249 | 0.88 | MAP2K7 (0.45) | PDE4BFPR3TSPOCRHR1TMEM97 | |
| Hydrochloric Acid SCHEMBL1637180 | 0.87 | MAP2K7 (0.44) | PDE4BFPR3TSPOCRHR1TMEM97 | |
| SCHEMBL12593337 | 0.87 | CRHR1 (0.39) | PDE4BFPR3TSPOCRHR1TMEM97 | |
| SCHEMBL1636814 | 0.86 | MAP2K7 (0.37) | FPR3TSPOCRHR1TMEM97MAP2K7 | |
| Hydrochloric Acid SCHEMBL1638286 | 0.85 | MAP2K7 (0.37) | FPR3TSPOCRHR1TMEM97MAP2K7 | |
| SCHEMBL1762498 | 0.84 | FFAR4 (0.41) | FFAR4 | |
| SCHEMBL1637091 | 0.84 | MAP2K7 (0.42) | PDE4BFPR3TSPOCRHR1TMEM97 | |
| SCHEMBL1638137 | 0.84 | CYP11B2 (0.37) | FPR3TSPOCRHR1TMEM97MAP2K7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | claimed |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-13 | — | — | US | claimed |
| EP-1953160-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-08-06 | — | — | EP | claimed |
| EP-1758903-A1 | PYRROLOPYRAMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-03-07 | — | — | EP | claimed |
| WO-2006001511-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | WO | claimed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951811-B2 | Antagonist against corticotropen releasing factor receptors; antidepressants, anxiolytic agents, Alzheimer's disease; Parkinson's disease; eating disorders; hypotensive agents; gastrointestinal disorders; drug abuse; brain disorders; antiischemic agents; antiinflammatory agents; immunotherapy; alopecia | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-05-26 | — | — | US | disclosed |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-11-13 | — | — | US | disclosed |
| EP-1953160-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1953160-A1 | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2008-08-06 | — | — | EP | disclosed |
| EP-1758903-A1 | PYRROLOPYRAMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006001511-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280928-A1 | Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with a Cyclic Amino Group As Crf Antagonists | CRHR1, CRHR2, HRH4 | FFAR4 107/4885PDE4B 334/4885FPR3 132/4885 |
| US-20110124862-A1 | PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH A CYCLIC AMINO GROUP AS CRF ANTAGONISTS | CRHR1, HRH2, CRHR2 | FFAR4 90/4885PDE4B 346/4885FPR3 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.